diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5393diaendo-5393Research ArticleСтатьиArticlesКардиоренальные взаимоотношения у больных сахарным диабетом 2 типа: новые данные исследования ADVANCECardiorenal relationships in patients with type 2 diabetes mellitus: new data of the ADVANCE studyШестаковаМарина ВладимировнаShestakovaMarina Vladimirovnanephro@endocrincentr.ru200915062009122№2 (2009)2527Copyright © Шестакова М.В., 20092009Шестакова М.В.Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5393

В исследовании ADVANCE прослеживается параллельное нарастание выраженности ренопротективного эффекта и предупреждения общей и сердечно-сосудистой смертности, что подтверждает гипотезу о взаимосвязи маркеров почечной и сердечно-сосудистой патологии. Исследование ADVANCE убедительно демонстрирует, что даже у пациентов СД2 старше 60 лет с высоким сердечно-сосудистым риском и длительным течением заболевания назначении в рутинной практике таких препаратов как диабетон?МВ и нолипрел форте безопасно и высокоэффективно, поскольку позволяет снизить риск развития и прогрессирования кардиоренального синдрома и сердечно-сосудистой смертности.

сахарный диабетдиабетическая нефропатияишемическая болезнь сердцаартериальная гипертонияdiabetes mellitusdiabetic nephropathycoronary heart diseasearterial hypertensionReferencesUS Renal Data System: USRDS 2007 Аnnual data report. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.US Renal Data System: USRDS 2007 Аnnual data report. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.Hovind P., Tarnow L., Rossing P. et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Br Med J. 2004; 328: 1105-1116.Hovind P., Tarnow L., Rossing P. et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Br Med J. 2004; 328: 1105-1116.Gall M.A., Rossing P., Skott P., Damsbo P. et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulindependent) diabetic patients.// Diabetologia.-1991.-Vol.34.-P.655-661.Gall M.A., Rossing P., Skott P., Damsbo P. et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulindependent) diabetic patients.// Diabetologia.-1991.-Vol.34.-P.655-661.DATAMONITOR Research and markets Brochure 2003. Diabetic Nephropathy: Prevalence, Progression, Prevention and Potential. More information from http://www.researchandmarkets.com/reports/38008/DATAMONITOR Research and markets Brochure 2003. Diabetic Nephropathy: Prevalence, Progression, Prevention and Potential. More information from http://www.researchandmarkets.com/reports/38008/Allen KV., Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care 2003; 26: 2389-2391.Allen KV., Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care 2003; 26: 2389-2391.Valmadrid CT., Klein R., Moss SE et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Int. Med. 2000; 160: 1093-1100.Valmadrid CT., Klein R., Moss SE et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Int. Med. 2000; 160: 1093-1100.Gerstein HC., Mann JFE., Yi Q. Et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-426.Gerstein HC., Mann JFE., Yi Q. Et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-426.Ibsen H., Wachtell K., Olsen MH et al. Reduction in microalbuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45: 1805-1811.Ibsen H., Wachtell K., Olsen MH et al. Reduction in microalbuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45: 1805-1811.de Zeeuw D., Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.de Zeeuw D., Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.Stehouwer CDА. Endotelial dysfunction in diabetic nephropathy: state of art and potential significance for non-diabetic renal disease. Nephrol.Dial.Transplant. 2004; 19: 778-781.Stehouwer CDА. Endotelial dysfunction in diabetic nephropathy: state of art and potential significance for non-diabetic renal disease. Nephrol.Dial.Transplant. 2004; 19: 778-781.Shestakova MV., Jarek-Mrtynowa IR., Ivanishiva NS.et al. Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diab. Res. And Clin. Practice 2005;.68 (suppl.1):S65-S72.Shestakova MV., Jarek-Mrtynowa IR., Ivanishiva NS.et al. Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diab. Res. And Clin. Practice 2005;.68 (suppl.1):S65-S72.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.www.advance-trial.comwww.advance-trial.com

The authors declare that there are no conflicts of interest present.